Cas:606136-19-0 N-(3,4-Difluorophenyl)-2-methylpyrimido[1,2-a]benzimidazol-4-amin e manufacturer & supplier

Chemical Name:N-(3,4-Difluorophenyl)-2-methylpyrimido[1,2-a]benzimidazol-4-amin e

CAS.NO:606136-19-0

Synonyms:N-(3,4-Difluorophenyl)-2-methylpyrimido[1,2-a]benzimidazol-4-amin e

Molecular Formula:C₁₇H₁₂F₂N₄

Molecular Weight:310.30100

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:N/A

Index of Refraction:

PSA:42.22000

Exact Mass:310.10300

LogP:4.28570

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like N-(3,4-Difluorophenyl)-2-methylpyrimido[1,2-a]benzimidazol-4-amin e chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,N-(3,4-Difluorophenyl)-2-methylpyrimido[1,2-a]benzimidazol-4-amin e physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,N-(3,4-Difluorophenyl)-2-methylpyrimido[1,2-a]benzimidazol-4-amin e Use and application,N-(3,4-Difluorophenyl)-2-methylpyrimido[1,2-a]benzimidazol-4-amin e technical grade,usp/ep/jp grade.

Related News: Countries and territories that have confirmed cases: Thailand, Japan, Hong Kong, Singapore, Taiwan, Australia, Malaysia, Macau, Russia, France, the United States, South Korea, Germany, the United Arab Emirates, Canada, Britain, Vietnam, Italy, India, the Philippines, Nepal, Cambodia, Sri Lanka, Finland, Sweden and Spain. N-(3,4-Difluorophenyl)-2-methylpyrimido[1,2-a]benzimidazol-4-amin e manufacturer At Day 35 following administration, a bone marrow assessment showed that FT819 persisted and continued to demonstrate tumor clearance, whereas primary CAR T cells, while persisting, were not able to control tumor growth. N-(3,4-Difluorophenyl)-2-methylpyrimido[1,2-a]benzimidazol-4-amin e supplier Countries and territories that have confirmed cases: Thailand, Japan, Hong Kong, Singapore, Taiwan, Australia, Malaysia, Macau, Russia, France, the United States, South Korea, Germany, the United Arab Emirates, Canada, Britain, Vietnam, Italy, India, the Philippines, Nepal, Cambodia, Sri Lanka, Finland, Sweden and Spain. N-(3,4-Difluorophenyl)-2-methylpyrimido[1,2-a]benzimidazol-4-amin e vendor At Day 35 following administration, a bone marrow assessment showed that FT819 persisted and continued to demonstrate tumor clearance, whereas primary CAR T cells, while persisting, were not able to control tumor growth. N-(3,4-Difluorophenyl)-2-methylpyrimido[1,2-a]benzimidazol-4-amin e factory The program will run alongside our ongoing Phase 3 INSPIRE Trial, and is expected to continue until commercial launch in such countries.